Plasma adiponectin is associated with less atherogenic lipoprotein phenotype

Area of Science:

• Cardiovascular Research
• Metabolic Syndrome
• Lipidology

Background:

• The atherogenic lipoprotein phenotype (ALP) is a cluster of lipid abnormalities associated with increased cardiovascular risk.
• Adiponectin, an adipokine, plays a role in glucose and lipid metabolism.
• Understanding the relationship between adiponectin and ALP features is crucial for cardiovascular disease prevention.

Purpose of the Study:

• To investigate the association between plasma adiponectin levels and the characteristics of the atherogenic lipoprotein phenotype (ALP).
• To examine the relationship between adiponectin and specific HDL subclasses and LDL particle size.

Main Methods:

• Cross-sectional study involving 293 healthy individuals.
• Measurement of blood lipids, apolipoproteins (apoB, apoAI), and insulin resistance (HOMA-IR).
• Analysis of LDL particle size and HDL subclasses (HDL(2), HDL(3)) using gradient gel electrophoresis.

Main Results:

• Plasma adiponectin levels showed significant correlations with various lipid parameters, including inverse relationships with apoB, triglycerides (TG), and HOMA-IR, and positive associations with apoAI, HDL-cholesterol, and LDL particle size.
• Adiponectin was independently associated with HDL-cholesterol levels, along with apoAI and TG.
• Specific correlations were observed between adiponectin and HDL subclasses, with positive links to HDL(2b) and HDL(2a), and negative links to HDL(3a), HDL(3b), and HDL(3c).

Conclusions:

• Circulating adiponectin levels are associated with reduced manifestations of the atherogenic lipoprotein phenotype.
• Adiponectin's relationship with HDL(2) subclasses appears independent of apoB and TG levels, suggesting a specific role in HDL metabolism.